Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 DiabetesPatrick R. Lawler, David Z.I. Cherney, Leif E. Lovblom et al.|Diabetes Care|2021Cited by 37
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetesHongyan Liu, David Z.I. Cherney, Vikas S. Sridhar et al.|Diabetes Obesity and Metabolism|2021Cited by 32
Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant RecipientsVikas S. Sridhar, Sunita Singh, Luxcia Kugathasan et al.|Clinical Journal of the American Society of Nephrology|2025Cited by 6
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled TrialVikas S. Sridhar, David Z.I. Cherney, Luxcia Kugathasan et al.|Hypertension|2025Cited by 1
Empagliflozin Is Associated with Increased Plasma Lipid Metabolites in Type 1 DiabetesHongyan Liu, David Z.I. Cherney, Daniel Scarr et al.|Journal of the American Society of Nephrology|2020Cited by 0